- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07232069
Prospektiv Randomiserad Utvärdering och Hantering av Förtida Åderförkalkning (PRE-EMPT) (PRE-EMPT)
Prospektiv Randomiserad Utvärdering och Hantering av Förtida Åderförkalkning
Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States. This clinical trial will test if screening and early treatment of mild heart disease works.
PRE-EMPT will screen individuals at low 10-year risk of heart disease with heart disease risk factors to identify those who already have early cholesterol build up, also called "plaque", in their heart arteries. It consists of two phases:
-
A Screening Study - Participants will be assessed for plaque by one or both of these scans.
- Coronary Artery Calcium (CAC) Scan: A CT scan that looks for calcium or plaque in heart arteries.
- Coronary CT Angiography (CCTA) Scan: A CT scan that uses contrast dye to create detailed 3D pictures of heart arteries to look for plaque.
-
A Treatment Trial (approximately 1,500 participants) - Based on the results of the CCTA, participants may be randomized into a two-year trial to test medications aimed at reducing or stabilizing plaque. Participants will have a 1 in 4 chance of receiving only placebo, and a 3 in 4 chance of receiving at least one active medication. Participants will take two pills once a day-either both active medications, one active and one placebo, or both placebos.
- Rosuvastatin 20 mg: a cholesterol-lowering medicine
- Colchicine 0.5 mg: a medication that lowers inflammation
Everyone in the trial will be given information and advice on heart-healthy diet and lifestyle.
Participants will have up to two in-person visits for the screening study, then phone visits for the Treatment Trial at the beginning, 3 months, 12 months and 24 months when they will also have an in-person visit for a CCTA Scan. Participants will have blood drawn using an at-home collection device mailed to their home at the beginning, 3 months, and end of the study.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The PRE-EMPT trial will be a 2x2 factorial, double-masked, placebo-controlled randomized trial of the effects of high-intensity statin and low-dose colchicine, alone and in combination, on CCTA-defined Non-Calcified Coronary Plaque (NCCP) volume at 2 years. Participants found through the screening study with CAC 1-99, or through the known plaque pathway, will be eligible for the trial if they have NCCP without severe stenosis or any other exclusion criteria. Study drug will be delivered directly to participants' homes, lab samples will be self-collected at home, and all study visits will be virtual except the imaging visits (up to 3 over 2 years). The only in-person study activities will be the CAC scan, if applicable, and CCTA at baseline and 2 years. The investigators anticipate that this approach will be attractive to middle-aged, busy individuals who are otherwise healthy and asymptomatic. Importantly, all participants in PRE-EMPT will receive an mHealth lifestyle intervention designed to support behavioral modification, ensuring that all individuals benefit from evidence-based strategies for cardiovascular risk reduction.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: Rachel Olson, Project Manager
- Telefonnummer: 919-309-5544
- E-post: rachel.e.olson@duke.edu
Studieorter
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35205
- Rekrytering
- University of Alabama at Birmingham
-
Huvudutredare:
- Kevin Riggs, MD
-
Kontakt:
- Dalton Norwood
- Telefonnummer: 909-786-8315
- E-post: daltonnorwood@uabmc.edu
-
Mobile, Alabama, Förenta staterna, 36608
- Rekrytering
- Cardiology Associates
-
Kontakt:
- Lynn Ward, RN BSN CCRC
- Telefonnummer: 251-607-9797
- E-post: lynnward@cardassoc.com
-
Huvudutredare:
- Jason Cole, MD
-
-
California
-
Los Angeles, California, Förenta staterna, 90095
- Rekrytering
- University of California, Los Angeles
-
Kontakt:
- Lynae Edmunds
- Telefonnummer: 310--210-9806
- E-post: laedmunds@mednet.ucla.edu
-
Huvudutredare:
- Karol Watson, MD
-
Los Angeles, California, Förenta staterna, 90502
- Rekrytering
- Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center
-
Kontakt:
- Sajad Hamal
- Telefonnummer: 310-974-9336
- E-post: shamal@lundquist.org
-
Huvudutredare:
- Matthew Budoff, MD
-
-
Georgia
-
Hiram, Georgia, Förenta staterna, 30141
- Rekrytering
- Wellstar Kennestone Hospital
-
Huvudutredare:
- Frank Corrigan, MD
-
Kontakt:
- Frank Corrigan, MD
- Telefonnummer: 678-324-4444
- E-post: frank.corrigan@wellstar.org
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60637
- Rekrytering
- University of Chicago
-
Huvudutredare:
- Tamar Polonsky, MD
-
Kontakt:
- Tamar Polonsky, MD
- Telefonnummer: 773-702-1409
- E-post: tpolonsky@bsd.uchicago.edu
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21287
- Har inte rekryterat ännu
- Johns Hopkins University
-
Kontakt:
- Prati Pratishruti, MBBS
- Telefonnummer: 410-301-1245
- E-post: fpratis1@jhu.edu
-
Huvudutredare:
- Michael Blaha, MD
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02114
- Rekrytering
- Massachusetts General Hospital Brigham
-
Kontakt:
- Pearl Lee, MSc
- Telefonnummer: 617-721-7783
- E-post: plee23@mgh.harvard.edu
-
Huvudutredare:
- Michael Honigberg, MD
-
-
Minnesota
-
Duluth, Minnesota, Förenta staterna, 55805
- Rekrytering
- Essentia Health
-
Kontakt:
- Martha Vanderlinde, BS
- Telefonnummer: 218-786-2729
- E-post: Martha.Vanderlinde@essentiahealth.org
-
Huvudutredare:
- Catherine Benzinger, MD
-
-
New York
-
Mount Kisco, New York, Förenta staterna, 10549
- Har inte rekryterat ännu
- Northern Westchester Hospital
-
Kontakt:
- Dina Katz, MD
- Telefonnummer: 914-762-5810
- E-post: PRE-EMPT@northwell.edu
-
Huvudutredare:
- Dina Katz, MD
-
New York, New York, Förenta staterna, 10021
- Rekrytering
- Weill Cornell Medicine
-
Kontakt:
- Dolores Reynolds, RN
- Telefonnummer: 212-746-4617
- E-post: dtr2001@med.cornell.edu
-
Huvudutredare:
- Sam Kim, MD
-
New York, New York, Förenta staterna, 10016
- Rekrytering
- New York University Langone
-
Huvudutredare:
- Harmony Reynolds, MD
-
Kontakt:
- Harmony Reynolds, MD
- Telefonnummer: 212-263-4320
- E-post: PREEMPT@nyulangone.org
-
-
North Carolina
-
Durham, North Carolina, Förenta staterna, 27710
- Rekrytering
- Duke University Hospital
-
Huvudutredare:
- Nishant Shah, MD
-
Kontakt:
- Niki Huffman
- Telefonnummer: 919-681-6458
- E-post: niki.huffman@duke.edu
-
Winston-Salem, North Carolina, Förenta staterna, 27157
- Rekrytering
- Wake Forest University, Advocate Health
-
Huvudutredare:
- Michael Shapiro, MD
-
Kontakt:
- Sophia Dawson, BA
- Telefonnummer: 336-713-2338
- E-post: Sophia.Dawson@advocatehealth.org
-
-
Oregon
-
Portland, Oregon, Förenta staterna, 97239
- Har inte rekryterat ännu
- Oregon Health and Sciences University
-
Kontakt:
- John Halvorson
- Telefonnummer: 503-418-1679
- E-post: halvorsj@ohsu.edu
-
Huvudutredare:
- Maros Ferencik, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19107
- Har inte rekryterat ännu
- Thomas Jefferson University
-
Kontakt:
- Caroline Freeman, BS
- Telefonnummer: 215-792-3872
- E-post: Caroline.Freeman@Jefferson.edu
-
Huvudutredare:
- Chris Chambers, MD
-
Pittsburgh, Pennsylvania, Förenta staterna, 15213
- Rekrytering
- University of Pittsburgh Medical Center
-
Huvudutredare:
- Anum Saeed, MD
-
Kontakt:
- Karli Drewencki
- Telefonnummer: 412-647-2931
- E-post: drewenckikr2@upmc.edu
-
-
South Carolina
-
Charleston, South Carolina, Förenta staterna, 29425
- Rekrytering
- Medical University of South Carolina (MUSC)
-
Huvudutredare:
- Sheldon Litwin, MD
-
Kontakt:
- Melissa Amitrano, MPH
- Telefonnummer: 843-876-5009
- E-post: amitrano@musc.edu
-
-
Tennessee
-
Nashville, Tennessee, Förenta staterna, 37203
- Har inte rekryterat ännu
- Vanderbilt University
-
Huvudutredare:
- Deepak Gupta, MD
-
Kontakt:
- Gabriella Davies Thoppil, MD MPH
- Telefonnummer: 615-421-1143
- E-post: g.thoppil@vumc.org
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030
- Rekrytering
- Houston Methodist Hospital
-
Kontakt:
- Peyton Martin
- Telefonnummer: 443-413-6350
- E-post: knasir@houstonmethodist.org
-
Huvudutredare:
- Khurrrram Nasir, MD
-
-
Virginia
-
Charlottesville, Virginia, Förenta staterna, 22903
- Rekrytering
- University of Virginia (UVA)
-
Kontakt:
- James Ingersoll
- Telefonnummer: 434-982-1058
- E-post: WFC5KC@uvahealth.org
-
Huvudutredare:
- Todd Villines, MD
-
Fairfax, Virginia, Förenta staterna, 22031
- Har inte rekryterat ännu
- Inova Health System
-
Kontakt:
- Mahira Awan
- Telefonnummer: 571-472-8570
- E-post: mahira.awan@inova.org
-
Huvudutredare:
- Jared Spitz, MD
-
-
Wisconsin
-
Marshfield, Wisconsin, Förenta staterna, 54449
- Rekrytering
- Marshfield Clinical Research Institute
-
Kontakt:
- Kelly Scheffen
- Telefonnummer: 715-221-7285
- E-post: preempt@marshfieldresearch.org
-
Huvudutredare:
- Jeff VanWormer
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Women aged 40-60 years; Men aged 30-50 years
- Willing and able to provide informed consent and comply with study procedures
- Smart phone user
- Use of highly effective contraception by females with reproductive potential.
- CAC score 1-99 in the screening study or entry through the known plaque pathway (with mild CAC or CAC<100 if known; elevated CAC on baseline CCTA is not exclusionary in the known plaque arm)
- Diagnostic baseline CCTA with NCPV ≥10 mm3 as assessed by the central core lab
Exclusion Criteria:
- Clinical diagnosis of ASCVD including coronary artery disease (CAD), peripheral arterial disease (PAD) or cerebrovascular disease (CeVD)
- Current symptoms thought to be from CAD
- PREVENT ASCVD 10-year risk ≥5% (if known)
- Diabetes Mellitus (DM) as defined by any of the following: DM diagnosis in the medical record or HbA1C of 6.5% or greater. (if known)
- LDL-C ≥190mg/dL (most recent, if known)
- HIV (if known)
- Severe liver disease or untreated Hepatitis C infection (if known)
- Pregnancy, lactation or intending to become pregnant during the study period of 2 years
- eGFR <45mL/min/1.73m2 (if known)
- AST or ALT >1.5x the upper limit of normal (if known)
- BMI>40kg/m2 or unable to have a CCTA scan for any reason
- Allergy to iodinated intravenous contrast or other contraindication to CCTA
- Current or previous use of lipid lowering therapy or colchicine
- Known allergic reactions or sensitivity to the study intervention(s), including known intolerance or contraindication(s) to statin or colchicine, or long-term use of medications that are contraindicated with colchicine or rosuvastatin.
- Systemic cancer undergoing active treatment
- PREVENT ASCVD 10-year risk ≥5%
- eGFR <45 ml/min/1.73m2 per baseline labs, (2021 CKD-EPI equation will be used if multiple options are available)
- Hemoglobin A1c ≥6.5% per baseline labs
- LDL-C ≥190mg/dL per baseline labs
- Severe proximal coronary artery stenosis as determined by the central core lab (≥50% left main or ≥70% proximal major coronary artery stenosis)
- Known contraindication to follow-up CCTA (e.g., new IV contrast allergy discovered during the baseline CCTA)
- Individuals who are excluded based on any of these factors will be notified as to the reason for exclusion and encouraged to follow-up locally to address this medical issue with their treating physician.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Faktoriell uppgift
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: rosuvastatin 20mg plus colchicine-matched placebo
statin plus placebo (two pills once daily) |
Statin
Andra namn:
Placebo, non-active, drug-matched |
|
Experimentell: colchicine 0.5mg plus rosuvastatin-matched placebo
anti-inflammatory plus placebo (two pills once daily) |
Placebo, non-active, drug-matched Anti-inflammatory
Andra namn:
|
|
Experimentell: rosuvastatin 20mg plus colchicine 0.5mg
statin plus anti-inflammatory (two pills once daily) |
Statin
Andra namn:
Anti-inflammatory
Andra namn:
|
|
Placebo-jämförare: placebo plus placebo
Placebo and placebo (two pills once daily) |
Placebo, non-active, drug-matched |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Non-calcified plaque volume (NCPV) on CCTA at 2 years, adjusted for baseline NCPV.
Tidsram: 2 years
|
Plaque volume in mm3 in each group |
2 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Förändring i LDL-kolesterol (low-density lipoprotein cholesterol)
Tidsram: Baseline till 2 år
|
Baseline till 2 år
|
|
|
Förändring av icke-HDL-kolesterol (icke-högdensitetslipoproteinkolesterol)
Tidsram: Baseline till 2 år
|
Baseline till 2 år
|
|
|
Number of participants with Drug Discontinuation
Tidsram: Up to 2 years
|
Drug Tolerability outcome |
Up to 2 years
|
|
Overall drug treatment adherence
Tidsram: Up to 2 years
|
Number of days on study drugs |
Up to 2 years
|
|
Safety events of special interest
Tidsram: Up to 2 years
|
Number of safety events of special interest per group |
Up to 2 years
|
|
Total plaque volume
Tidsram: Up to 2 years
|
Plaque volume in mm3 per group |
Up to 2 years
|
|
Low-attenuation plaque volume
Tidsram: Up to 2 years
|
Low attenuated plaque volume in mm3 per group |
Up to 2 years
|
|
Calcified plaque volume
Tidsram: Up to 2 years
|
Calcified plaque volume in mm3 per group |
Up to 2 years
|
|
Number of participants with stenosis
Tidsram: Up to 2 years
|
Number of participants with stenosis per group |
Up to 2 years
|
|
Segment involvement score
Tidsram: Up to 2 years
|
Average score per group |
Up to 2 years
|
|
Number of participants with qualitative calcified, partially calcified and non-calcified plaque composition
Tidsram: Up to 2 years
|
Number of participants with each plaque composition description per group |
Up to 2 years
|
|
Number of participants with High-risk plaque features (positive remodeling, spotty calcium, napkin ring sign)
Tidsram: Up to 2 years
|
Number of participants with each plaque feature (high-risk) per group |
Up to 2 years
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- Pro00118744
- UG3HL181434 (U.S.S. NIH-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .